These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 16312139)

  • 1. Febuxostat (Teijin/Ipsen/TAP).
    Tomlinson B
    Curr Opin Investig Drugs; 2005 Nov; 6(11):1168-78. PubMed ID: 16312139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and pharmacodynamics of febuxostat (TMX-67), a non-purine selective inhibitor of xanthine oxidase/xanthine dehydrogenase (NPSIXO) in patients with gout and/or hyperuricemia.
    Komoriya K; Hoshide S; Takeda K; Kobayashi H; Kubo J; Tsuchimoto M; Nakachi T; Yamanaka H; Kamatani N
    Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1119-22. PubMed ID: 15571213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase.
    Takano Y; Hase-Aoki K; Horiuchi H; Zhao L; Kasahara Y; Kondo S; Becker MA
    Life Sci; 2005 Mar; 76(16):1835-47. PubMed ID: 15698861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
    Ernst ME; Fravel MA
    Clin Ther; 2009 Nov; 31(11):2503-18. PubMed ID: 20109996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout.
    Becker MA; Schumacher HR; Wortmann RL; MacDonald PA; Palo WA; Eustace D; Vernillet L; Joseph-Ridge N
    Arthritis Rheum; 2005 Mar; 52(3):916-23. PubMed ID: 15751090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Febuxostat: a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout.
    Bruce SP
    Ann Pharmacother; 2006 Dec; 40(12):2187-94. PubMed ID: 17132810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers.
    Becker MA; Kisicki J; Khosravan R; Wu J; Mulford D; Hunt B; MacDonald P; Joseph-Ridge N
    Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1111-6. PubMed ID: 15571211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Febuxostat for prevention of gout attacks.
    Pohar S; Murphy G
    Issues Emerg Health Technol; 2006 Aug; (87):1-4. PubMed ID: 16958189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Febuxostat: a non-purine, selective inhibitor of xanthine oxidase for the management of hyperuricaemia in patients with gout.
    Schumacher HR
    Expert Opin Investig Drugs; 2005 Jul; 14(7):893-903. PubMed ID: 16022578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Febuxostat versus allopurinol for gout.
    Lustberg ME
    N Engl J Med; 2006 Apr; 354(14):1532-3; author reply 1532-3. PubMed ID: 16598054
    [No Abstract]   [Full Text] [Related]  

  • 11. [Febuxostat].
    Wittköpper K; Emons J; El-Armouche A
    Dtsch Med Wochenschr; 2011 Jun; 136(23):1270-4. PubMed ID: 21607898
    [No Abstract]   [Full Text] [Related]  

  • 12. The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase.
    Khosravan R; Kukulka MJ; Wu JT; Joseph-Ridge N; Vernillet L
    J Clin Pharmacol; 2008 Sep; 48(9):1014-24. PubMed ID: 18635756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Febuxostat: new drug. Hyperuricaemia: risk of gout attacks.
    Prescrire Int; 2009 Apr; 18(100):63-5. PubMed ID: 19585722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Febuxostat (Uloric) for chronic treatment of gout.
    Med Lett Drugs Ther; 2009 May; 51(1312):37-8. PubMed ID: 19448587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Febuxostat: a novel non-purine selective inhibitor of xanthine oxidase for the treatment of hyperuricemia in gout.
    Yu KH
    Recent Pat Inflamm Allergy Drug Discov; 2007 Feb; 1(1):69-75. PubMed ID: 19075968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Febuxostat versus allopurinol for gout.
    Gelber AC
    N Engl J Med; 2006 Apr; 354(14):1532-3; author reply 1532-3. PubMed ID: 16602151
    [No Abstract]   [Full Text] [Related]  

  • 17. Febuxostat for gout.
    Drug Ther Bull; 2010 Jul; 48(7):78-82. PubMed ID: 20631196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PK/PD and safety of a single dose of TMX-67 (febuxostat) in subjects with mild and moderate renal impairment.
    Hoshide S; Takahashi Y; Ishikawa T; Kubo J; Tsuchimoto M; Komoriya K; Ohno I; Hosoya T
    Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1117-8. PubMed ID: 15571212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gout therapeutics: new drugs for an old disease.
    Burns CM; Wortmann RL
    Lancet; 2011 Jan; 377(9760):165-77. PubMed ID: 20719377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).
    Ojha R; Singh J; Ojha A; Singh H; Sharma S; Nepali K
    Expert Opin Ther Pat; 2017 Mar; 27(3):311-345. PubMed ID: 27841045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.